Shifting Medicine Forward

Drawing on a deep understanding of the underlying causes, Ichnos Sciences is pursuing truly disease-centric therapies in oncology. We strive to develop novel assets and find new answers to some of medicine’s greatest challenges. Because the world is waiting.

Our path toward disease-centric therapies

Oncology Pipeline
Candidate Target Preclinical Phase 1 Phase 2 Phase 3 Status
ISB 1342 CD38 x CD3 BEAT® 1.0
bispecific antibody
Relapsed/Refractory Multiple Myeloma
      Phase 1 Enrolling
ISB 1909 BEAT® 2.0 T cell engager bispecific antibody
Undisclosed
      Discovery
ISB 1442 CD38 x CD47 BEAT® 2.0 bispecific antibody
Hematologic Malignancies
      IND-Enabling Studies
ISB 2004 BEAT® 2.0 bispecific antibody
Undisclosed
      Discovery
ISB 2001 TREAT™ trispecific antibody
Undisclosed
      Discovery
oncology pipeline
Compound:
ISB 1342
Target:
CD38 x CD3 BEAT® 1.0
bispecific antibody
Indication:
Relapsed/Refractory Multiple Myeloma
Phase:
phase-1
Status:
Phase 1 Enrolling
Compound:
ISB 1909
Target:
BEAT® 2.0 T cell engager bispecific antibody
Indication:
Undisclosed
Phase:
preclinical
Status:
Discovery
Compound:
ISB 1442
Target:
CD38 x CD47 BEAT® 2.0 bispecific antibody
Indication:
Hematologic Malignancies
Phase:
preclinical
Status:
IND-Enabling Studies
Compound:
ISB 2004
Target:
BEAT® 2.0 bispecific antibody
Indication:
Undisclosed
Phase:
preclinical
Status:
Discovery
Compound:
ISB 2001
Target:
TREAT™ trispecific antibody
Indication:
Undisclosed
Phase:
preclinical
Status:
Discovery

BEAT®Bispecific Engagement by Antibodies based on the T cell Receptor
TREAT™: Trispecific Engagement by Antibodies based on the T cell Receptor

Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.

Out-licensing opportunities available for biologics in autoimmune diseases.

Learn more

View Career Opportunities

United States

Switzerland

The links above are provided for your convenience, and Ichnos is not responsible for content, privacy or security issues associated with your visit to external websites.